<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401268</url>
  </required_header>
  <id_info>
    <org_study_id>ScIG alloHCT</org_study_id>
    <nct_id>NCT03401268</nct_id>
  </id_info>
  <brief_title>Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients</brief_title>
  <acronym>ScIGalloHCT</acronym>
  <official_title>A Pilot Study to Assess Tolerability of Subcutaneous Immunoglobulin Treatment (Hizentra) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tolerability of home subcutaneous immunoglobulin (ScIG) for replacement therapy for&#xD;
      hypogammaglobulinemia in allogeneic HCT patients. A financial analysis comparing the cost of&#xD;
      ScIG with intravenous immunoglobulin (IVIG) will also be performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to determine whether home subcutaneous immunoglobulin (ScIG) is&#xD;
      tolerated as replacement therapy for hypogammaglobulinemia in patients that have undergone&#xD;
      allogeneic hematopoietic cell transplantation (alloHCT). Secondary objective is to perform a&#xD;
      financial analysis comparing the cost of ScIG with intravenous immunoglobulin (IVIG). The&#xD;
      study hypothesis is that home based SCIG treatment is applicable and tolerated well for&#xD;
      replacement treatment in alloHCT patients. This will be examined in two sets of patients&#xD;
      recruited: A) Patients already on IVIG replacement therapy and B) Newly diagnosed patients&#xD;
      with hypogammaglobulinemia. Economic analysis will be performed by comparing the cost with an&#xD;
      equal number of patients retrospectively determined to have undergone treatment with IVIG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">May 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of home ScIG as replacement therapy for hypogammaglobulinemia in allogeneic transplant patients</measure>
    <time_frame>6 months</time_frame>
    <description>Qualitative survey describing tolerability, QOL assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Financial analysis of cost of ScIG in allogeneic HCT patients</measure>
    <time_frame>1 year</time_frame>
    <description>A cost comparison will be performed between the ScIG population and a retrospectively assessed population of allogeneic HCT patients that received IVIG. This will be assessed by a financial analysis and retrospective chart review.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypogammaglobulinemia</condition>
  <arm_group>
    <arm_group_label>Patient cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study population will include 24 patients, that are either already on IVIG or are eligible for ScIG as initial Ig replacement, that will undergo Ig replacement with subcutaneous immunoglobulin (ScIG) for a total of 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous immunoglobulin</intervention_name>
    <description>24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.</description>
    <arm_group_label>Patient cohort</arm_group_label>
    <other_name>ScIG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Patients at least 100 days post allogeneic hematopoietic cell transplantation for any&#xD;
             benign or malignant hematological disease, from a related or unrelated donor&#xD;
&#xD;
          -  Patients who are already established on regular IVIG&#xD;
&#xD;
          -  Patients eligible for immunoglobulin replacement with an IgG &lt;7mg/L, or normal IgG&#xD;
             total but IgG2 or IgG4 below normal&#xD;
&#xD;
          -  Patients with IgG =&gt;7g/L but with at least 2 prior episodes of bacterial infection&#xD;
             (proven or suspected eg. sinusitis diagnosed on CT)&#xD;
&#xD;
          -  No other medical condition which would preclude treatment with immunoglobulin&#xD;
&#xD;
          -  Willing to participate and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous serious adverse reaction from IVIG or products from Hizentra (polysorbate)&#xD;
&#xD;
          -  Other serious medical or psychiatric disorders which may interfere with the patient's&#xD;
             ability to participate in the study, or interfere with study assessment (e.g. advanced&#xD;
             congestive heart failure, severe liver disease, renal failure, disease relapse or&#xD;
             secondary malignancy, schizophrenia, paranoid psychosis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fotios V. Michelis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypogammaglobulinemia</keyword>
  <keyword>allogeneic hematopoietic cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agammaglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

